I disagree. Lots of work has been completed after the previous trial to get us where we are now. That being in investigation of the biomarkers and other indications etc. The company is well placed with a potential of a platform drug.
We are still some way away from paydirt milestones. Until we arrive there the share price will drift. The good news is, upticks are being better supported volume wise than pullbacks. So this would suggest the price should run hard when the time arrives.
PER Price at posting:
7.8¢ Sentiment: Buy Disclosure: Held
